Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 2,808 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: cyclophosphamide Clear all

Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions: rQNestin, Cyclophosphamide, Stereotactic biopsy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: T-cell Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Graft-versus-host Disease
Interventions: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 60 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions: cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing; Drug · Biological · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
Interventions: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2); Procedure · Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida • Tampa, Florida

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 4
States / cities: Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Cyclophosphamide, Daratumumab, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Interventions: Indoximod, Ibrutinib, Cyclophosphamide, Etoposide, Temozolomide; Drug
Lead sponsor: Theodore S. Johnson; Other
Eligibility: 3 Years to 25 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Lymphoma
Interventions: bevacizumab, filgrastim, pegfilgrastim, bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, zidovudine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: cyclophosphamide, dexamethasone, lenalidomide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: trastuzumab, carboplatin, carmustine, cisplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 2
States / cities: Boston, Massachusetts • Hackensack, New Jersey

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263, FCR, BR; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Stanford, California • Baltimore, Maryland + 3 more

Conditions: Large B-Cell Lymphoma
Interventions: Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 60
States / cities: Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more

Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
Interventions: MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing; Biological · Drug · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Non Hodgkin Lymphoma, B Cell Leukemia
Interventions: CD19 specific Chimeric Antigen Receptor T Cell; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Cutaneous Melanoma
Interventions: fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL, Aldesleukin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC; Drug · Biological · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B-Cell Malignancies
Interventions: Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Detroit, Michigan + 4 more

Conditions: Breast Cancer
Interventions: Taxotere, Adriamycin/cytoxan; Drug
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematological Malignancy
Interventions: Bortezomib; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Refractory Breast Carcinoma
Interventions: Cyclophosphamide, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Pembrolizumab, Recombinant Interferon Alpha 2b-like Protein, Questionnaire Administration, Quality of Life Assessment; Drug · Biological · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Interventions: Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous), Mesna; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

MOv19-BBz CAR T Cells in FRa+ Cancers

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Drosophila-generated CTL

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Biologic Correlative Taxotere/AC

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies